Business profile & competitive position
Ulta Beauty, Inc. operates inside the Consumer Cyclical sector as a Specialty Retail name, running a chain of beauty superstores that sell cosmetics, fragrance, skin care, hair care, and salon services. That classification matters: it is not a defensive staple retailer; its sales ride discretionary spending on beauty and self-care products.
The numbers Ulta posts are better than what many specialty retailers produce. A net margin of 9.4% is well above the low-single-digit margins common in broadline retail, and a return on equity of 44.8% is unusually high for the group. In specialty retail, ROE in the mid-teens to mid-twenties is typical, so a 44.8% reading points to strong pricing power, scale in purchasing, a large loyalty program, and efficient inventory turns. The key caveat is leverage: because ROE can be magnified by debt levels, an investor should check the balance sheet to see how much of that 44.8% comes from operating efficiency versus financial leverage. Still, on its face, the margin and ROE combination suggests Ulta occupies a stronger competitive position than the average specialty retailer, with a brand and store footprint that let it protect profitability.
Financial posture
As of the snapshot, Ulta traded at roughly $554.16 with a $23.8 billion market cap and a 20.7 P/E, putting it near—but not far above—the broader market multiple for a company with above-average margins. The 9.4% net margin supports that valuation by showing the company turns a decent slice of revenue into bottom-line profit, while the 44.8% ROE indicates management has historically generated strong returns on shareholder capital.
The stock’s beta of 0.85 suggests it has moved less sharply than the overall market, fitting a relatively mature consumer cyclical. Technical context is also worth noting: the price sits nearly $53 above the 50-day EMA of $501.30, and the RSI is 70.2, right at the traditional overbought threshold. That combination tells you momentum has been strong, but it also flags how much of the recent move may already be priced in. Nothing in these figures alone is a buy or sell signal; they simply describe a company that looks fundamentally healthy on profitability but is no longer technically cheap.
Macro & geopolitical exposure
Because Ulta is a Consumer Cyclical / Specialty Retail business, its top-line is exposed to the health of the consumer. Employment levels, wage growth, savings rates, and consumer confidence all influence how much shoppers spend on discretionary beauty items. A slowdown in those inputs typically hits this sector faster than it hits utilities, healthcare, or staples.
Beyond household finances, specialty retail also faces import and tariff exposure. Cosmetics, packaging, and many component ingredients are sourced globally, especially from Asia, so changes in trade policy can alter cost structures or margins. Currency fluctuations, freight costs, and port congestion can add another layer of volatility. On the regulatory side, product-safety rules, ingredient restrictions, and state-level labeling requirements affect what retailers can stock and how they market it. Finally, as a brick-and-mortar-heavy specialty retailer, Ulta is exposed to mall and strip-traffic trends, labor costs, and the broader shift between in-store and online beauty shopping.
Recent developments
The headline flow around Ulta has been busy heading into its next report. On August 10, 2026, Zacks published “Earnings Growth & Price Strength Make Ulta Beauty (ULTA) a Stock to Watch,” noting the company’s earnings momentum and price performance. Just days earlier, on August 4, 2026, Zacks also ran “Ulta Beauty (ULTA) Increases Yet Falls Behind Market: What Investors Need to Know,” a reminder that the stock can rise while still trailing broader market gains.
On August 3, 2026, two very different stories hit the tape. BusinessWire reported that Adagio Medical treated its first patient with a faster, single-freeze next-generation ULTA System—a medical-device development that has nothing to do with Ulta Beauty beyond the shared “ULTA” ticker shorthand. The same day, Defense World noted that Edgestream Partners L.P. purchased 3,631 shares of Ulta Beauty Inc. That is a small position, but it still registers as institutional interest. Readers scanning news feeds should distinguish between ticker-derived noise like the Adagio release and company-specific items about Ulta Beauty itself.
Earnings behavior & post-earnings drift
Ulta’s earnings history shows a strong reporting record but a more complicated price reaction than many traders assume. Over the last eight reported quarters, Ulta has beaten expectations 6 times, for a 75% beat rate, and its average earnings surprise has been a solid 10.1%. Yet the average 5-day move after earnings across those quarters is -2.44%, classified as a down post-earnings drift. That disconnect—frequent beats but negative average follow-through—is the most important pattern to understand.
The last four quarters make the point clearly. On June 2, 2026, Ulta reported $7.74 EPS against a $6.89 estimate, a 12.3% beat, but the stock fell -4.78% the next day and -3.43% over the following five. On March 12, 2026, it missed by -1.1% with $8.01 versus $8.10, and the selloff was severe: -14.24% the next session and -14.5% over five days. The December 4, 2025 report delivered $5.14 against $4.61, an 11.5% beat, and produced a strong +12.65% one-day gain and +11.14% over five days. But the August 28, 2025 quarter showed another beat—$5.78 vs. $5.10, a 13.3% surprise—yet the stock dropped -7.14% the next day and -2.97% over the next five sessions.
So while beats are the norm and the average surprise is large, the market has not reliably rewarded those beats. Forward guidance, valuation compression, or simply high expectations embedded in the price often matter more than the headline EPS beat. Looking ahead, Ulta is scheduled to report next on August 27, 2026 after the close, with the consensus EPS estimate at $6.17. That estimate is the market’s real expectation heading into the print, but the recent history shows a beat alone does not guarantee a pop or a hold.
Frequently Asked Questions
What does ULTA’s 75% beat rate tell us?
It tells us Ulta has exceeded the consensus EPS estimate in six of its last eight quarters. What it does not tell us is direction after the report. The average 5-day post-earnings drift over that same span is -2.44%, which shows a strong beat rate does not automatically translate into a sustained stock-price gain.
Is the Adagio Medical “ULTA System” news related to Ulta Beauty?
No. The August 3, 2026 BusinessWire item about a next-generation ULTA System refers to a medical product from Adagio Medical. It only shares a ticker-like abbreviation with Ulta Beauty. Investors should check the source before assuming every “ULTA” headline is about the beauty retailer.
How should the RS I at 70.2 be read alongside the 50-day EMA?
An RSI of 70.2 is at the traditional overbought boundary, while the stock price near $554.16 sits roughly $53 above the 50-day EMA of $501.30. Both readings describe strong near-term momentum, not a forecast. They simply add context to the fundamental picture of a high-margin, high-ROE specialty retailer.
For a deeper dive into ULTA, review the full institutional verdict on our platform, where analyst ratings, consensus estimates, and historical surprise data are rolled into a single view.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-06-02 | $7.74 | $6.89 | +12.3% | -4.78% | -3.43% |
| 2026-03-12 | $8.01 | $8.1 | -1.1% | -14.24% | -14.5% |
| 2025-12-04 | $5.14 | $4.61 | +11.5% | +12.65% | +11.14% |
| 2025-08-28 | $5.78 | $5.1 | +13.3% | -7.14% | -2.97% |
| 2025-05-29 | $6.7 | $5.81 | +15.3% | - | - |
| 2025-03-13 | $8.46 | $7.13 | +18.7% | - | - |
Previous ULTA editions
Get the institutional verdict on ULTA
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the ULTA verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.